Autoantibodies in psoriatic patients treated with anti‐TNF‐α therapy

Abstract

An increased autoantibody titer is not predictive of treatment failure; particular attention to all phenomena suggestive for autoimmunity is needed in patients with a positive autoantibody titer. Further studies are needed to clarify the role of autoantibodies during anti-TNF- α therapy.

Patient reports of the frequency and severity of adverse reactions associated with biological agents prescribed for psoriasis in Brazil

“…Case reports have described paradoxical induction of autoimmune processes associated with biological agents [19][20][21]. TNF-a inhibitors decrease serum levels of inflammatory markers such as TNF-a itself, C-reactive protein, IL-6 and increase the tissue expression of endothelial nitric oxide synthase and the vasodilatory response to bradykinin.…”

Antinuclear antibody formation following administration of anti‐tumor necrosis factor agents in Japanese patients with psoriasis

“…1,2 The present study demonstrated that treatment of psoriasis patients with anti-TNF agents, unlike ustekinumab, significantly increased the proportion of patients who were positive for ANA without the development of autoimmune diseases or loss of response.…”

“…Although the pathogenesis of IgAV in patients with HIV infection remains unclear, increased circulation of immune complexes associated with the HIV infection or local replication of HIV itself may cause vasculitis. 1 To our knowledge, four cases of IgAV with HIV infection have been reported. [2][3][4][5] Three of those cases, [3][4][5] and the current case, showed a high plasma viral load of 3-447 9 10 4 copies/ mL or a decreased CD4 count of 15-64 9 10 6 /L.…”

A dermatologist guide to immunogenicity

“…In another PsA study, 37% of 128 patients treated with anti-TNFα drug developed autoantibodies (Bardazzi et al, 2014). Almost half (48.48 %) of those who received infliximab developed autoantibodies (Bardazzi et al, 2014).…”